Source comparison
CJC-1295 No DAC & Ipamorelin: Peptide Comparison
CJC-1295 No DAC (Modified GRF 1-29) 30 minutes 15–20 minutes 90–120 minutes GHRH receptor agonist. Amplifies GH pulse amplitude 1–3x daily Ideal for pulsatile protocols that mimic natural circadian GH secretion without receptor desensitisation Ipamorelin 2 hou
This comparison does not assign a generated winner or score.
- CJC-1295 No DAC (Modified GRF 1-29)
- 30 minutes
- 15–20 minutes
- 90–120 minutes
- GHRH receptor agonist. Amplifies GH pulse amplitude
- 1–3x daily
- Ideal for pulsatile protocols that mimic natural circadian GH secretion without receptor desensitisation
- Ipamorelin
- 2 hours
- 30–45 minutes
- 3–4 hours
- Ghrelin receptor agonist. Extends GH pulse duration without cortisol/ACTH release
- Clean GH release with minimal off-target effects; synergises with GHRH analogues for peak amplitude + duration
- CJC-1295 With DAC
- 6–8 days
- 24–48 hours
- 7–14 days
- GHRH receptor agonist with albumin binding. Creates sustained elevation
- 1x weekly
- Long half-life risks receptor desensitisation and suppression of endogenous pulsatile GH secretion over time
- GHRP-2
- 20–30 minutes
- 15–30 minutes
- 60–90 minutes
- Ghrelin receptor agonist. Strong GH release with mild cortisol/prolactin elevation
- 2–3x daily
- Potent but less selective than ipamorelin; useful in research models requiring robust GH stimulation
- MK-677 (Ibutamoren)
- 24 hours
- 24+ hours
- Oral ghrelin mimetic. Sustained GH and IGF-1 elevation
- 1x daily
- Elevates baseline GH between injected pulses; pairs well with short-acting peptides for hybrid protocols